Searchable abstracts of presentations at key conferences in endocrinology

ea0028n1.3 | Thyroid eye disease | SFEBES2012

My thyroid eye disease journey

McLaren Julie

At 39 I was diagnosed with Thyroid Eye Disease (TED) and commenced on Prednisolone by my Endocrinology team. There followed 18 months under my local Eye Hospital. I was started on Azathioprine. The Prednisolone was then gradually decreased to nil and then the Azathioprine decreased to nil. Now that my TED was inactive I transferred to Moorfields Eye Hospital (MEH). In 1 year I had bilateral lateral wall decompressions, bilateral upper lid surgery & bilateral lower lid surg...

ea0094p3 | Adrenal and Cardiovascular | SFEBES2023

Assessing the Impact of Residual Adrenal Function on the prevalence of adrenal crises and intercurrent infections

Lynch Julie , McLaren David , Cassidy Samantha , Kyriakakis Nikolaos , Seejore Khyatisha , Murray Robert

Objective: Determinants of why only a subset of patients with adrenal insufficiency (AI) experience recurrent adrenal crises (AC) and intercurrent illnesses are not well understood. This study aimed to identify whether residual adrenal function (RAF), defined by the peak response to a provocative test undertaken before commencing glucocorticoids, may help explain differences in prevalence.Design and Methods: Patients wit...

ea0028p342 | Thyroid | SFEBES2012

Orbital decompression for graves’ orbitopathy in england

Perros Petros , Chandler Tracy , Dayan Colin , Dickinson Alison , Foley Peter , Hickey Janis , MacEwen Caroline , Lazarus John , Rose Geoffrey , Uddin Jimmy , Vaidya Bijay , McLaren Julie

Graves’ orbitopathy affects approximately 0.25 million people in the UK and is associated with a significant psychological and socioeconomic burden. Surveys have illustrated that Graves’ orbitopathy is often treated inadequately. The Amsterdam Declaration is a recent incentive supported by many national and international professional and patient-led organizations including the SfE, aiming to improve the outcomes of patients with Graves’ orbitopathy. This report ...

ea0094op1.3 | Neuroendocrinology and Pituitary | SFEBES2023

Biochemical control does not improve functional impairment in people with acromegaly

Z Safdar Nawaz , Heague Megan , Hebden Sophie , Lynch Julie , Mclaren David , Tresoldi Alberto , Lithgow Kirstie , Urwyler Sandrine , Akbar Shahzad , McLoughlin Katie , Kearney Tara , Drake William M. , Sathyapalan Thozhukat , Orme Steve , E Higham Claire , Karavitaki Niki , Kyriakakis Nikolaos , Murray Robert

Acromegaly, a chronic disorder of excessive growth hormone secretion, leads to functional limitation and impaired mobility most commonly due to arthropathy. Patients with biochemically controlled acromegaly have reported persistent impairment in prior studies. We aimed to compare the functional differences in patients with biochemically controlled acromegaly to those with uncontrolled disease by means of validated questionnaires. Between March 2017 and May 2022, patients over ...

ea0094p233 | Neuroendocrinology and Pituitary | SFEBES2023

Characterisation of the Impact of Joint Pain on Patients with Acromegaly

Hebden Sophie , Safdar Nawaz , Heague Megan , Lynch Julie , Mclaren David , Tresoldi Alberto , Lithgow Kirstie , Urwyler Sandrine , Akbar Shahzad , McLoughlin Katie , Kearney Tara , M Drake William , Sathyapalan Thozhukat , Orme Steve , E Higham Claire , Karavitaki Niki , Kyriakakis Nikolaos , Murray Robert

Acromegaly is caused by excessive growth hormone (GH) and insulin-like growth factor (IGF-1) secretion. Arthropathy is a leading cause of morbidity and impaired quality of life in acromegalic patients, often persisting despite therapeutic interventions and biochemical control. This cross-sectional study aimed to characterise the extent and impact of arthropathy in terms of pain and functional impairment. Validated questionnaires, including DASH (Disabilities of the Arm, Should...